Posted by Michael Wonder on 28 Mar 2019
FDA approves treatment for patients with a type of inflammatory arthritis
28 March 2019 - The U.S. FDA today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation.
This is the first time that the FDA has approved a treatment for nr-axSpA.
The efficacy of Cimzia for the treatment of nr-axSpA was studied in a randomized clinical trial in 317 adult patients with nr-axSpA with objective signs of inflammation, indicated by elevated C-reactive protein (CRP) levels and/or sacroiliitis (inflammation of the sacroiliac joints) on MRI.
